Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Neoadjuvant chemotherapy plus immunotherapy (nCT + ICIs) and neoadjuvant chemoradiotherapy plus immunotherapy (nCRT + ICIs) both induced favorable pathological response and tolerant toxicities for locally resectable esophageal squamous cell carcinoma (ESCC). However, few studies compared safety and efficacy between the two treatment strategies.
Methods: This retrospective study collected clinical data of locally resectable ESCC patients who underwent nCT + ICIs or nCRT + ICIs followed by esophagectomy from November 2019 to December 2022. The incidence of adverse events, surgical outcomes, short and long-term efficacy, and treatment costs were compared.
Results: A total of 206 patients were included, with a ratio of 158:48 between nCT + ICIs group and nCRT + ICIs group. The two groups exhibited well-balanced baseline characteristics. Most adverse events were grade 1-2 in both groups. The nCT + ICIs group had a longer operative time (334.00 ± 170.2 min vs 279.60 ± 88.31 min, =0.020) than nCRT + ICIs group, but there were no differences in surgical complications. Although nCT + ICIs group had a lower pCR rate (32.3% vs 52.1%, =0.004), the 2-year overall survival (84.42% vs 81.70%, =0.860), 2-year disease-free survival (83.21% vs 80.47%, =0.839), and recurrence patterns were similar to nCRT + ICIs group. In addition, nCT + ICIs group had significantly lower expenses (188796.00 ± 107704.00 RMB vs 231808.00 ± 48067.00 RMB, =0.045).
Conclusion: Overall, nCT + ICIs have comparable safety and efficacy compared to nCRT + ICIs for locally resectable ESCC, but with lower hospitalization costs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11109365 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1336798 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Neoadjuvant Chemotherapy with or without Immune Checkpoint Inhibitors for Resectable Esophageal Squamous Cell Carcinoma: a Meta-analysis of Randomized Controlled Trials.
J Gastrointest Cancer
August 2025
Department of Medical Oncology, The First People's Hospital of Linping District, Hangzhou, 311100, Zhejiang Province, China.
Background: Recently, there has been significant attention focused on neoadjuvant immune checkpoint inhibitors combined with chemotherapy (NICT) for the treatment of resectable esophageal squamous cell carcinoma (ESCC). In order to assess the efficacy and safety of this innovative combination in relation to traditional neoadjuvant chemotherapy (NCT), we performed a systematic meta-analysis of randomized controlled trials (RCTs).
Methods: A comprehensive review of the literature was performed across Embase, Cochrane Library, Web of Science, and PubMed, covering the period from their inception to May 2, 2025, to identify appropriate RCTs.
Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapies.
J Exp Clin Cancer Res
July 2025
Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.
Background: Metastatic uveal melanoma (mUM) is a rare malignancy and is different from metastatic cutaneous melanoma (mCM) in tumor characteristics and efficacy to immunotherapies. Tumor-specific biomarkers are required for mUM patients to monitor early disease progression on immunotherapies.
Methods: We investigated clinical characteristics such as liver tumor burden and routine blood tumor markers, including lactate dehydrogenase (LDH) and transaminases in patients with mUM and with liver metastasized cutaneous melanoma (LmCM), treated with immune checkpoint inhibitors (ICIs) between May 2013-February 2024.
Expression signatures with specificity for type I and II IFN response and relevance for autoimmune diseases and cancer.
J Transl Med
July 2025
Clinical Measurement Sciences, Merck Healthcare KGaA, Oncology Data Science, Darmstadt, Germany.
Background: Aberrant interferon signaling is a key element of various diseases, but resolving gene expression signatures that stem from different types of IFNs in tissue samples is still a challenge. Most published IFN signatures comprise genes that are activated by different IFNs: they cannot discriminate type-I (IFN-I) and type-II (IFN-II) IFN stimulation. Most often such signatures were obtained from a single expression dataset that had been obtained in a specific cellular context, and their translatability to other experimental contexts has not been demonstrated.
View Article and Find Full Text PDFEfficacy and safety of immunotherapy-based neoadjuvant regimens in locally advanced gastric cancer: a meta-analysis based on high-quality clinical trials.
Int J Surg
June 2025
Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
Background: The integration of chemotherapy, targeted therapy, and immunotherapy has emerged as the latest research focus for locally advanced gastric cancer (LAGC). This study aims to evaluate the efficacy and safety of various immunotherapy-based neoadjuvant regimens for LAGC.
Methods: PubMed, EmBase, and Cochrane Library databases were systematically searched based on the predefined inclusion criteria.
Enhancing survival in locally advanced esophageal cancer: a comparative analysis of neoadjuvant immunotherapy versus conventional neoadjuvant therapies using the SEER database.
J Thorac Dis
May 2025
Department of Medical Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China.
Background: Neoadjuvant immune checkpoint inhibitors (ICIs) for locally advanced esophageal cancer have drawn significant research interest. We used the Surveillance, Epidemiology, and End Results (SEER) database to explore survival benefits of neoadjuvant immunotherapy (NAI) in this group.
Methods: A comprehensive analysis was conducted utilizing the SEER database to assess the efficacy of NAI in conjunction with surgery compared to traditional neoadjuvant therapy.